Loading clinical trials...
Loading clinical trials...
The Efficacy and Safety of Anti-PD-1 Antibody in Combination With Pegaspargase in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Conditions
Interventions
Pegaspargase
Anti-PD-1 monoclonal antibody
Locations
1
China
Ruijin hospital
Shanghai, Shanghai Municipality, China
Start Date
September 10, 2019
Primary Completion Date
December 1, 2021
Completion Date
December 1, 2022
Last Updated
March 11, 2020
NCT01787409
NCT03493451
NCT02168140
NCT01769222
NCT01523223
NCT01261247
Lead Sponsor
Ruijin Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions